Search results for "OSTEOPOROSI"

showing 10 items of 434 documents

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures

2019

Summary Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures. Introduction The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach. Methods Clinical perspective and updated literature search. Results The following areas are reviewed: …

0301 basic medicinemedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismeducationOsteoporosisPsychological interventioninhibitors of bone resorption030209 endocrinology & metabolismRisk AssessmentAnabolic agents03 medical and health sciencesTherapeutic approach0302 clinical medicineBone DensityRisk FactorsTreatment of osteoporosisInternal medicinemedicinefracture risk assessmentHumansanabolic agentsIntensive care medicineOsteoporosis PostmenopausalAgedAnabolic agents Fracture risk assessment FRAX Inhibitors of bone resorption Treatment of osteoporosisddc:616Postmenopausal womenbusiness.industryCorrectionFracture risk assessmentInhibitors of bone resorptionMiddle Agedtreatment of osteoporosismedicine.diseaseRheumatologyIncreased riskFemalePosition Paper030101 anatomy & morphologybusinessVery high riskAlgorithmsOsteoporotic FracturesFRAXOsteoporosis International
researchProduct

Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?

2016

Since the mid-1980s, postmenopausal osteoporosis (PMO) has been considered a serious public health concern because of the associated fractures. Pharmacological therapies that effectively reduce the number of fractures by improving bone mass have been and are being developed continuously. Most current agents inhibit bone loss by reducing bone resorption, but emerging therapies may increase bone mass by stimulating bone formation. Furthermore, nowadays, the most representative pharmaceuticals have been prescribed long enough to include the reporting of some adverse effects. This review discusses osteoporotic drugs that are approved or are under investigation for the treatment of post-menopaus…

0301 basic medicinemedicine.medical_specialtyLong term treatmentTime Factorsmedicine.medical_treatmentRomosozumab030209 endocrinology & metabolismPostmenopausal osteoporosisBone resorption03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectOsteoporosis PostmenopausalPharmacologybusiness.industryPublic healthBisphosphonateSurgery030104 developmental biologyDenosumabFemalebusinessmedicine.drugEuropean journal of pharmacology
researchProduct

Can a healthy life prevent us from post-menopausal osteoporosis? Myths and truths

2016

Abstract Postmenopausal osteoporosis is related to unmodifiable risk factors (genetics, race, gender and age). However, other controllable factors such as activity, body mass, hormone and calcium levels and dietary habits can reduce fracture risk. For example, significant increases in bone mass density have been linked to physical activity in children, supplements of Vitamin C taken for more than 10 years, or high consumption of fish, olive oil or dried plums. This review establishes the scientific basis behind these non-pharmaceutical practices and summarizes a number of basic studies and clinical trials involving them as well as discusses their potential for the osteoporosis treatment. A …

0301 basic medicinemedicine.medical_specialtyOsteoporosisPhysiology030209 endocrinology & metabolism03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineEpidemiologyMedicinePharmacology (medical)Adverse effectPharmacology030109 nutrition & dieteticsVitamin Cbusiness.industryIsoflavonesmedicine.diseaseClinical trialEndocrinologychemistryOvariectomized ratBiomarker (medicine)businessFood SciencePharmaNutrition
researchProduct

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct

Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher d…

2018

Anca Zimmermann,1 Radu A Popp,2 Heidi Rossmann,3 Simona Bucerzan,4 Ioana Nascu,4 Daniel Leucuta,5 Matthias M Weber,1 Paula Grigorescu-Sido41Department of Endocrinology and Metabolic Diseases, 1st Clinic and Polyclinic of Internal Medicine, University of Mainz, Mainz, Germany; 2Department of Medical Genetics, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 3Institute for Clinical Chemistry and Laboratory Medicine, University of Mainz, Mainz, Germany; 4Center of Genetic Diseases, 1st Pediatric Clinic, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 5Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy, Cluj-Napoca, RomaniaPurpose: Oste…

0301 basic medicinemusculoskeletal diseasesmedicine.medical_specialtyTherapeutics and Clinical Risk ManagementOsteoporosisGaucher diseasegene variantsCalcitriol receptorBone remodeling03 medical and health sciencesOsteoprotegerinInternal medicineGenotypecalcitonin receptormedicinevitamin D receptorPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsCalcitonin receptorOriginal ResearchChemical Health and Safetybiologybusiness.industryGeneral Medicinemedicine.diseaseosteoporosis030104 developmental biologyEndocrinologyosteoprotegerinOsteocalcinbiology.proteinbusinessSafety ResearchEstrogen receptor alphaTherapeutics and Clinical Risk Management
researchProduct

Effects of High-Impact Training on Bone and Articular Cartilage: 12-Month Randomized Controlled Quantitative MRI Study

2013

Osteoarthritis and osteoporosis often coexist in postmenopausal women. The simultaneous effect of bone-favorable high-impact training on these diseases is not well understood and is a topic of controversy. We evaluated the effects of high-impact exercise on bone mineral content (BMC) and the estimated biochemical composition of knee cartilage in postmenopausal women with mild knee osteoarthritis. Eighty women aged 50 to 66 years with mild knee osteoarthritis were randomly assigned to undergo supervised progressive exercise three times a week for 12 months (n = 40) or to a nonintervention control group (n = 40). BMC of the femoral neck, trochanter, and lumbar spine was measured by dual-energ…

030203 arthritis & rheumatologymedicine.medical_specialtyTrochanterbusiness.industryEndocrinology Diabetes and MetabolismCartilageOsteoporosis030209 endocrinology & metabolismCardiorespiratory fitnessOsteoarthritisIsometric exercisemedicine.disease3. Good health03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureAnesthesiaCollagen networkPhysical therapyMedicineOrthopedics and Sports MedicinebusinessFemoral neckJournal of Bone and Mineral Research
researchProduct

The Impact of Estrogen Decline on Other Noncommunicable Diseases

2017

Estrogens have specific receptors spread out in various systems of the organism. The drastic hormonal fall after menopause may be followed by a series of effects, which may be more or less relevant in the different areas of the organism. The bone constitutes a field that clearly reflects that impact, and postmenopausal osteoporosis has received attention in one ad hoc chapter. The present chapter reviews the impact on functions of the central nervous system, particularly cognition and mood, the skeletal system, specifically osteoarthritis, and the cardiovascular system. The obvious interest of the chapter derives from the importance of the selected systems, which may house highly prevalent …

030219 obstetrics & reproductive medicinemedicine.drug_classbusiness.industryCognitionPostmenopausal osteoporosisBioinformaticsmedicine.diseaseMenopause03 medical and health sciences0302 clinical medicineMoodEstrogenmedicinebusiness030217 neurology & neurosurgeryOrganism
researchProduct

Personality of Fragility Fractures of the Pelvis

2017

The personality of pelvic fractures in the elderly differs in many ways from pelvic ring lesions in adults. Only high-energy trauma leads to pelvic ring disruptions. Concomitant lesions of the soft tissues occur frequently. In the elderly, low-energy falls are the rule. The most important symptom is pain, which restricts mobility. Hemodynamic instability in fragility fractures of the pelvis is rare. Emergency stabilization with pelvic binders or sheets, C-clamping or emergency external fixation are not needed. Arteriography and selective embolization is only recommended in the rare patients, who develop an active arterial bleeding due to the pelvic fracture. Especially patients, who are tre…

030222 orthopedicsmedicine.medical_specialtyCallus formationbusiness.industrymedicine.medical_treatmentOsteoporosis030208 emergency & critical care medicinePubic symphysismedicine.diseaseSacrumSurgerybody regions03 medical and health sciencesExternal fixation0302 clinical medicinemedicine.anatomical_structureAla of sacrummedicinePelvic fracturebusinessPelvis
researchProduct

Implicación de las vías Nrf2/HO-1 y NADPH oxidasa en los modelos experimentales de artritis y osteoporosis postmenópausicas.

2012

Hemos puesto a punto y caracterizado el modelo de artritis postmenopáusica mediante ovariectomía (OVX) y artritis inducida por colágeno (CIA). Además, hemos estudiado la influencia de la vía HO-1 en este modelo animal mediante la administración de tin protoporfirina IX (SnPP) (inhibidor reversible de HO-1) y de CORM-3 (molécula liberadora de CO), así como la influencia de la vía NADPH oxidasa mediante el empleo de ratones con una modificación genética en Ncf1 de manera que no producen especies reactivas del oxigeno por esta vía. En la caracterización del modelo de artritis postmenopáusica, OVX-CIA, se ha demostrado que el déficit de estrógenos potencia la respuesta inflamatoria y facilita e…

:CIENCIAS MÉDICAS::Farmacodinámica::Mecanismos de acción de los medicamentos [UNESCO]artritis; osteoporosisUNESCO::CIENCIAS MÉDICAS::Farmacodinámica::Mecanismos de acción de los medicamentos:CIENCIAS MÉDICAS::Farmacología::Evaluación de medicamentos [UNESCO]osteoporosisartritisUNESCO::CIENCIAS MÉDICAS::Farmacología::Evaluación de medicamentos
researchProduct

Ruolo dell’esercizio fisico sulla densità minerale ossea e sui markers del turnover osseo in donne in post-menopausa

2014

ATTIVITA' FISICAOSTEOPOROSI
researchProduct